Supriya Gupta

US Patent:

7612102, Nov 3, 2009

Filed:

Apr 18, 2007

Appl. No.:

11/788076

Inventors:

Michelle Renee Duncan - Glenview IL, US
Supriya Gupta - Sunnyvale CA, US
David Hartley Haas - Fremont CA, US
Norma V. Stephens - Skokie IL, US
Camellia Zamiri - Fremont CA, US

International Classification:

A61K 31/44

US Classification:

514354, 424400

Abstract:

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

US Patent:

7659290, Feb 9, 2010

Filed:

Mar 19, 2009

Appl. No.:

12/407551

Inventors:

Michelle Renee Duncan - Glenview IL, US
Supriya Gupta - Sunnyvale CA, US
David Hartley Haas - Fremont CA, US
Norma V. Stephens - Skokie IL, US
Camellia Zamiri - Fremont CA, US

Assignee:

EKR Therapeutics, Inc. - Bedminster NJ

International Classification:

A61K 31/44

US Classification:

514354, 424400

Abstract:

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

US Patent:

7659291, Feb 9, 2010

Filed:

Mar 19, 2009

Appl. No.:

12/407557

Inventors:

Michelle Renee Duncan - Glenview IL, US
Supriya Gupta - Sunnyvale CA, US
David Hartley Haas - Fremont CA, US
Norma V. Stephens - Skokie IL, US
Camellia Zamiri - Fremont CA, US

Assignee:

EKR Therapeutics, Inc. - Bedminster NJ

International Classification:

A61K 31/44

US Classification:

514354, 424400

Abstract:

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

US Patent:

8298530, Oct 30, 2012

Filed:

Aug 12, 2009

Appl. No.:

12/540320

Inventors:

Elizabet A. Kaisheva - Belmont CA, US
Aleni Flores-Nate - Union City CA, US
Supriya Gupta - Sunnyvale CA, US

Assignee:

Facet Biotech Corporation - Redwood City CA

International Classification:

A61K 39/395

US Classification:

4241301, 4241411, 4241441

Abstract:

This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e. g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5. 5 to about 6. 5, about 0. 005%-0. 03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

US Patent:

8455524, Jun 4, 2013

Filed:

Dec 17, 2010

Appl. No.:

12/971084

Inventors:

Michelle Renee Duncan - Glenview IL, US
Supriya Gupta - Sunnyvale CA, US
David Hartley Haas - Fremont CA, US
Norma V. Stephens - Skokie IL, US
Camellia Zamiri - Fremont CA, US

Assignee:

EKR Therapeutics, Inc. - Cary NC

International Classification:

A61K 31/44

US Classification:

514354, 424400

Abstract:

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

US Patent:

8465739, Jun 18, 2013

Filed:

Sep 6, 2011

Appl. No.:

13/226372

Inventors:

Elizabet A. Kaisheva - Belmont CA, US
Supriya Gupta - Sunnyvale CA, US
Shanti G. Duvur - Fremont CA, US
Malathy Subramanian - Fremont CA, US

Assignee:

Abbvie Biotherapeutics Inc. - Redwood City CA

International Classification:

A61K 39/395

US Classification:

4241301, 4241411, 4241441

Abstract:

This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e. g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5. 5 to about pH 6. 5, about 0. 01-0. 1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8 C. ) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

US Patent:

8466178, Jun 18, 2013

Filed:

Dec 22, 2009

Appl. No.:

12/645169

Inventors:

Michelle Renee Duncan - Glenview IL, US
Supriya Gupta - Sunnyvale CA, US
David Hartley Haas - Fremont CA, US
Norma V. Stephens - Skokie IL, US
Camellia Zamiri - Fremont CA, US

Assignee:

EKR Therapeutics, Inc. - Cary NC

International Classification:

A61K 31/44

US Classification:

514354, 424400

Abstract:

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

US Patent:

8466179, Jun 18, 2013

Filed:

Dec 23, 2010

Appl. No.:

12/977965

Inventors:

Michelle Renee Duncan - Glenview IL, US
Supriya Gupta - Sunnyvale CA, US
David Hartley Haas - Freemont CA, US
Norma V. Stephens - Skokie IL, US
Camellia Zamiri - Fremont CA, US

Assignee:

EKR Therapeutics, Inc. - Cary NC

International Classification:

A61K 31/44

US Classification:

514354, 424400

Abstract:

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Address:

927 Robin Way, Sunnyvale, CA 94087

Phone:

4087300122

VIN:

2HNYD2H28BH539693

Make:

ACURA

Model:

MDX

Year:

2011